RxDoctor Payments Data

Charles Smith, MD

Family Medicine · Granbury, TXNPI 1790780930

Payments from drug & device makers

$9,099in general payments, 2019–2025

Across 559 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$903
  • AstraZeneca$748
  • Lilly USA, LLC$596
  • Boehringer Ingelheim$492
  • Takeda Pharmaceuticals U.S.A., Inc.$421
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,94198%
  • Education$1412%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)104$1,390
Novo Nordisk58$903
AstraZeneca38$748
Lilly USA, LLC39$596
Boehringer Ingelheim23$492
Takeda Pharmaceuticals U.S.A., Inc.29$421
Amgen(2 entities)23$399
Otsuka America Pharmaceutical, Inc.21$372
Amarin Pharma, Inc.23$352
Exact Sciences16$321
Abbott15$306
Astellas Pharma US Inc11$242
Pfizer14$239
Merck12$161
Kowa Pharmaceuticals America, Inc.10$154
Bayer13$141
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$136
Novartis7$133
Eisai Inc.6$123
Arbor Pharmaceuticals, Inc.9$122
Sanofi-aventis U.S. LLC7$119
Esperion Therapeutics, Inc.8$119
Currax Pharmaceuticals LLC8$108
Mylan Specialty L.p.4$83
Dexcom, Inc.3$57
Radius Health, Inc.3$53
Johnson & Johnson3$48
Vivus LLC4$46
Acella Pharmaceuticals, LLC2$44
GSK3$43
Antares Pharma, Inc.2$42
Biohaven Pharmaceutical Holding Company Ltd.2$42
Ironshore Pharmaceuticals Inc.2$39
Teva Pharmaceuticals USA, Inc.3$37
Axsome Therapeutics, Inc.2$36
Phathom Pharmaceuticals, Inc.2$35
Paratek Pharmaceuticals, Inc.1$23
Tolmar, Inc.1$23
Shield Therapeutics Inc1$21
Corcept Therapeutics1$20
Viatris Specialty LLC1$20
Alnylam Pharmaceuticals Inc.1$19
Biogen1$17
IBSA Pharma Inc.1$17
Optos, Inc.1$17
Lundbeck LLC1$17
Biohaven Pharmaceuticals, Inc.1$17
Tris Pharma Inc1$16
Globus Medical1$16
Inspire Medical Systems, Inc.1$16
Xeris Pharmaceuticals, Inc.1$16
Therapeuticsmd, Inc.1$16
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$15
Si-bone, Inc.1$15
Collegium Pharmaceutical, Inc.1$15
Pernix Therapeutics Holdings, Inc.1$14
Nalpropion Pharmaceuticals LLC1$13
Nestle Healthcare Nutrition Inc.1$13
Ironwood Pharmaceuticals, Inc1$12
Genentech USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,099 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$170,361
Medicare patients
515
Services billed
2,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$175,187
EliquisApixaban110$113,751
TrulicityDulaglutide91$113,473
JardianceEmpagliflozin62$87,628
MounjaroTirzepatide58$75,623
ForteoTeriparatide12$49,552
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog60$49,409
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog41$48,894
MyrbetriqMirabegron50$36,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$35,041
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$31,454
FarxigaDapagliflozin Propanediol20$28,898
JanumetSitagliptin Phos/Metformin Hcl19$23,102
RybelsusSemaglutide13$22,234
XareltoRivaroxaban14$17,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Forteo$596$238,648161 claims
Novo NordiskOzempic, Rybelsus$903$197,421139 claims
PfizerEliquis$239$113,751110 claims
Boehringer IngelheimJardiance$492$87,62862 claims
AstraZenecaBreztri Aerosphere, Farxiga$748$60,35362 claims
MerckJanumet, Januvia, Janumet Xr$161$48,56848 claims
GSKTrelegy Ellipta, Breo Ellipta$43$42,85164 claims
Astellas Pharma US IncMyrbetriq$242$36,45050 claims
Johnson & JohnsonXarelto$48$17,49914 claims
AbbVieSynthroid$1,390$15,134175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →